Half year Median Technologies liquidity contract statement contracted with Louis Capital Markets UK LLP

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With iBiopsy® we are disrupting the management of serious diseases such as lung cancer, liver cancer, and NASH. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. iBiopsy® is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

Learn More

Request a Demo

Press release – For immediate release – 5:45 pm CEST

Half year Median Technologies liquidity contract statement contracted with Louis Capital Markets UK LLP

Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) to Louis Capital Markets UK LLP, the following resources were listed in the liquidity account as of June 30, 2020:

32,518 shares
€77,124.37 in cash

Transactions during the first half 2020:

BUY	114,265 shares	455,351.48 EUR	183 transactions
SELL	86,151 titres	359,264.84 EUR	259 transactions

For information, as of May 4^th, 2020, when the new liquidity contract was set up, the following resources were listed in the liquidity account:

4,404 shares
€173,829.64 in cash

Back to press releases